arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PACB
$1.18 ▲ +0.01 (+1.29%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
18 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $354.0M
Dividend Yield
Revenue Growth 3.9%
Op. Margin -346.2%
ROIC -10360.5%
FCF / Share $-0.38
Trailing P/E
Price / Book 66.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$160.00M
↑ +3.9%
Net Income Profit after all expenses
$-546.38M
↓ -76.3%
Operating Margin Operating profit as % of sales
-346.2%
↓ -12.4% 0th
FCF / Share Free cash flow per share
$-0.38
↑ +50.9%
Long-Term Debt Long-term obligations
$896.68M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
15
Cash Quality
29

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters